Our extensive global network of manufacturing facilities in geographically diverse locations support our efforts to ensure reliable supply, and our facilities are routinely inspected by a number of health authorities globally. In 2019 alone, our facilities underwent more than 135 inspections around the world.
Our pipeline fuels the future
Our pipeline and research and development capabilities, which are focused on investments to continue moving the company up the value chain, include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a wide range of product types. We work to address unmet needs through science and innovation to bring important medicines to market, such as our pending once-monthly glatiramer acetate, a generic Symbicort®, a biosimilar to Avastin®, a biosimilar to Eylea® and biosimilar to Botox®, and serve patients at every stage of life.1 Some examples of our capabilities include:
- Biosimilars and insulin analogs
- Respiratory products
- Complex sterile products
- Topicals and transdermals
- Complex oral solid dosage forms
- High potency products
- Traditional generics
- Drug/device combinations
1COPAXONE is a registered trademark of Teva Pharmaceuticals Industries Ltd.
ADVAIR DISKUS is a registered trademark of Glaxo Group Limited.
SYMBICORT is a registered trademark of AstraZeneca AB.
BOTOX is a registered trademark of Allergan, Inc.
AVASTIN is a registered trademark of Genentech, Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.
PFIZER is a registered trademark of Pfizer Inc.
The information contained on this page is not for use in product detailing or promotion.
*Not all of the products listed have been approved for use in all countries. To learn which products have been approved for use in a particular country, please visit that country’s page for a full listing of available drug products.